The Amyotrophic Lateral Sclerosis (ALS) Association will continue funding of a project designed to find biomarkers that indicate the presence of ALS, or Lou Gehrig’s Disease.

RTP-based Metabolon is part of the consortium involved in the project.

Specifics of the funding were not disclosed.

“The project has already produced a candidate panel of molecules in body fluids that differ between people with the disease and those who do not have ALS,” Metabolon said in a statement.